Open AccessGlucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes
Author(s) -
Elisabeth Ng,
Jonathan E. Shaw,
A. K. W. Wood,
Louise Maple-Brown,
M. J. Hare
Publication year - 2022
Publication title -
australian journal of general practice
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.421
H-Index - 42
eISSN - 2208-794X
pISSN - 2208-7958
DOI - 10.31128/ajgp-07-21-6057
Subject(s) - type 2 diabetes , medicine , weight loss , liraglutide , adverse effect , diabetes mellitus , hypoglycemia , agonist , incidence (geometry) , obesity , endocrinology , intensive care medicine , receptor , physics , optics
Type 2 diabetes (T2D) is a national health priority. Its rising prevalence is accompanied by a high burden of diabetes-related complications, many of which are preventable. Numerous glucose-lowering medications have been developed in recent years with growing evidence relating to their efficacy and safety. These advances have increased the complexity of prescribing decisions in T2D.